Innocare's Oral Psoriasis Drug Fadeucravacitinib Meets Primary Goal in Phase III Trial, Regulatory Filing Planned
Key Insights
Innocare Pharma (search)'s oral drug fadeucravacitinib (search) demonstrated a consistent treatment effect in a Phase III trial for moderate-to-severe plaque psoriasis (search).
Multiple secondary endpoints were also successfully met, supporting the drug's efficacy across measures, according to the company.
The Beijing-based firm plans to advance regulatory filing for fadeucravacitinib (search) following completion of the late-stage study.
Chinese drugmaker Innocare Pharma (search) announced on Monday that its experimental oral treatment fadeucravacitinib (search) met its primary goal in a late-stage clinical trial for moderate-to-severe plaque psoriasis (search), positioning the company to compete with Western pharmaceutical rivals in an expanding global market.
Plaque psoriasis (search) is a chronic disease characterized by red, scaly, inflamed patches on the skin. According to data cited by Innocare, approximately 8.66 million people in China live with psoriasis, and that number is on the rise.
The company stated that "multiple secondary endpoints were successfully met, demonstrating a consistent treatment effect across efficacy measures." Innocare added that it plans to advance regulatory filing for fadeucravacitinib (search) following completion of its Phase III study.
A Growing Oral Treatment Landscape
The global psoriasis market has been largely dominated by injectable therapies, but oral pills such as Bristol Myers Squibb (search)'s Sotyktu and Amgen's Otezla have emerged as convenient alternatives for patients. Innocare is not alone in pursuing this space — other drugmakers, including Takeda Pharmaceutical (search), are also developing experimental oral treatments for the condition.
Beijing-based Innocare specializes in drugs for the treatment of cancer and autoimmune diseases. The company's statement did not indicate in which countries it planned to seek regulatory approval for fadeucravacitinib (search).
Next Steps
With the Phase III study now demonstrating a consistent treatment effect, Innocare is poised to move toward regulatory submissions. The company has not yet disclosed detailed efficacy data or specific timelines for filing, but the successful completion of the late-stage trial marks a significant milestone for one of China's emerging autoimmune-focused biopharmaceutical firms.